Is Biohaven Ltd. (BHVN) a Buy, Sell, or Hold?
Biohaven Ltd.
NYSE:BHVN
$14.94 USD
-$0.23 (-1.52%)
- Volume
- 1.43M
- Average Volume
- 2.87M
- Market Capitalization
- $1.58B
- P/E Ratio
- -2.63
- Dividend Yield
- 0.00%
- Price Target
- $16.50
- Year High
- $18.57
- Year Low
- $7.48
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.41
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Vladimir Coric |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BHVN |
| CUSIP | G1110E107 |
| CIK | 0001935979 |
| Web | https://www.biohaven.com |
| Phone | 203 404 0410 |
| Currency | USD |
| Employees | 274 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 2.21 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.41 |
| Quick Ratio | 7.41 |
| Cash Ratio | 5.24 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -4.03 |
| Price / Cash Flow | -2.66 |
| Price / Book | 17.03 |
Price Target and Rating
| Average Stock Price Forecast | $16.50 |
| High Stock Price Forecast | $23.00 |
| Low Stock Price Forecast | $10.00 |
| Forecast Upside/Downside | -9.45% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 25 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-6.86 |
| Trailing P/E Ratio | -2.63 |
| PEG Ratio | -0.05 |
| P/E Growth | -0.05 |
| Net Income | $-738.82M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -866.46% |
| Return on Assets | -138.87% |
Financials Score
| AltmanZ Score | -7.43 |
| Piotroski Score | 2.00 |
| Working Capital | 333.57M |
| Total Assets | 466.41M |
| Ebit | -646.57M |
| Market Cap | 1.65B |
| Total Liabilities | 336.91M |
Poll Results
About Biohaven Ltd. (NYSE:BHVN) Stock
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions. ...
Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk
2026-07-13 08:17:31
Biohaven's pipeline is now more focused after having to narrow down its R&D efforts to other assets. Today, I think opakalim's pivotal epilepsy readout is probably the most important near-term catalyst that could validate their pipeline. They also have interesting, albeit early, positive findings with BHV-1300 and BHV-1400 for their degrader platform.
Biohaven Announces Scientific Leadership Transitions
2026-07-09 17:00:00
David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery Bruce Car, Ph.D.
2026-06-30 07:30:00
Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026 Emerging opakalim focal epilepsy and idiopathic generalized epilepsy data presented at recent R&D Day reinforce evidence of target engagement, potential for efficacy, and differentiated tolerability profile In the ongoing focal epilepsy open-label extension (OLE) study, 54% of participants on opakalim 75 mg once-daily achieved a ≥50% reduction in seizure frequency compared to pre-randomization baseline, with a markedly lower incidence of nervous system adverse events compared to approved and investigational ASMs High double-blind completion rates of ~95%, and high rollover rates into the OLE of ~95%, reflect favorable patient experience with opakalim NEW HAVEN, Conn., June 30, 2026 /PRNewswire/ -- Biohaven Ltd.
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
2026-06-29 14:04:13
Biohaven Ltd. (NYSE:BHVN) shares fell Monday after Bank of America Securities (BofA) downgraded the biotechnology company, citing an unfavorable risk-reward profile ahead of a key late-stage epilepsy trial.
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday's Pre-Market Session
2026-06-29 08:11:03
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Monday.
2026-06-29 07:30:00
BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a new class of precision immunology medicines that eliminate the disease-driving antibodies at the root of autoimmune disease. BHV-1300 targets the TSHR-IgG1 autoantibody that drives Graves' disease, not the thyroid gland itself.
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations
2026-06-18 15:28:24
Biohaven (BHVN) is upgraded from "Hold" to "Buy," driven by FDA regulatory shifts and strong biomarker data for its protein degrader pipeline. The company is set to initiate pivotal studies for BHV-1300 in Graves' Disease and BHV-1400 in IgA Nephropathy in mid-2026, targeting large unmet markets. Phase 1b data show over 80% reduction in pathogenic TSHR-IgG1 for BHV-1300 and over 60% Gd-IgA1 reduction for BHV-1400, with safety advantages over competitors.
2026-06-01 07:30:00
BHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addressing the bioenergetic and immunometabolic basis of systemic and central nervous system disorders First-in-human study initiated with dose escalation ongoing; preliminary data in healthy participants demonstrates favorable pharmacokinetics supporting convenient, once-daily dosing and well a tolerated profile at projected therapeutic exposures Penetrates blood-brain barrier and reverses metabolic dysfunction with 3-fold improvement in glucose utilization in human, whole brain model (Bexorg BrainEx platform, physiologically reactivated brains from human donors); preferential metabolic rescue in Alzheimer's disease donor brains vs controls Exhibits robust beneficial effects across a spectrum of preclinical models of Alzheimer's, and multiple sclerosis: restores metabolic deficits, reduces inflammation and neurodegeneration, and enhances remyelination PKM2 modulation offers a potential new paradigm for treating large, underserved, and high-value indications in neurology, ophthalmology, and immunology NEW HAVEN, Conn., June 1, 2026 /PRNewswire/ -- Biohaven Ltd.
Frequently Asked Questions
-
What is the current Biohaven Ltd. (BHVN) stock price?
-
Biohaven Ltd.(NYSE:BHVN) stock price is $14.94 in the last trading session. During the trading session, BHVN stock reached the peak price of $18.566 while $7.48 was the lowest point it dropped to. The percentage change in BHVN stock occurred in the recent session was --1.52% while the dollar amount for the price change in BHVN stock was -$-0.23.
-
BHVN's industry and sector of operation?
-
The NYSE listed BHVN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BHVN?
-
Warren Volles | General Counsel & Chief Legal Officer
Bruce D. Car DACVP | Chief Scientific Officer
Vladimir Coric | Chairman & Chief Executive Officer
Clifford Bechtold | President, GM of Biohaven Ireland & Chief Compliance Officer
George C. Clark | Vice President & Chief Accounting Officer -
How many employees does BHVN have?
-
Number of BHVN employees currently stands at 274. BHVN operates from 215 Church Street, New Haven, CT 06510, US.
-
Link for BHVN official website?
-
Official Website of BHVN is: https://www.biohaven.com
-
How do I contact BHVN?
-
BHVN could be contacted at phone #203 404 0410 and can also be accessed through its website. BHVN operates from 215 Church Street, New Haven, CT 06510, US.
-
How many shares of BHVN are traded daily?
-
The average number of BHVN shares traded daily for last 3 months was 2.87M.
-
What is the market cap of BHVN currently?
-
The market value of BHVN currently stands at $1.58B with its latest stock price at $14.94